Skip to main content

Table 1 Clinical characteristics of the patients studied

From: Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP

UPN Age/sex Disease Duration of lung disease (months) Medication at presentation FVC/DLCO
1 77/M RA-UIP 0 No therapy 75.3/47.2
2 71/F RA-UIP 12 PDN/AZA/NAC 68.7/22.1
3 75/F RA-UIP 0 No therapy 89.7/34.8
4 72/M RA-UIP 0 MTX-LEFLUNEMIDE* 119.3/68.4
5 76/F RA-UIP 6 PDN/AZA/NAC 82.8/60.1
6 50/F RA-UIP 12 PDN/AZA/NAC 94.5/49.6
7 81/F RA-UIP 0 No therapy 76.5/32
8 74/M IPF 0 No therapy 70/70
9 78/M IPF 0 No therapy 41.6/25
10 82/M IPF 0 No therapy 75.6/38.5
11 85/M IPF 0 No therapy 88/31
12 70/M IPF 0 No therapy 83/58
13 72/M IPF 0 No therapy 75/45
  1. Abbreviations: PDN: prednisolone, MTX: methotrexate, AZA: azathioprine, NAC: N-acetyl-cysteine, UPN: unique patient number.
  2. * The patient was on treatment for Rheumatoid Arthritis.